AU2022280804A1 - Substituted carbamate macrocyclic compounds and related methods of treatment - Google Patents
Substituted carbamate macrocyclic compounds and related methods of treatment Download PDFInfo
- Publication number
- AU2022280804A1 AU2022280804A1 AU2022280804A AU2022280804A AU2022280804A1 AU 2022280804 A1 AU2022280804 A1 AU 2022280804A1 AU 2022280804 A AU2022280804 A AU 2022280804A AU 2022280804 A AU2022280804 A AU 2022280804A AU 2022280804 A1 AU2022280804 A1 AU 2022280804A1
- Authority
- AU
- Australia
- Prior art keywords
- alkylene
- alkyl
- cycloalkyl
- formula
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163193256P | 2021-05-26 | 2021-05-26 | |
| US63/193,256 | 2021-05-26 | ||
| PCT/US2022/030841 WO2022251304A1 (en) | 2021-05-26 | 2022-05-25 | Substituted carbamate macrocyclic compounds and related methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022280804A1 true AU2022280804A1 (en) | 2023-11-30 |
Family
ID=82156598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022280804A Pending AU2022280804A1 (en) | 2021-05-26 | 2022-05-25 | Substituted carbamate macrocyclic compounds and related methods of treatment |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240174689A1 (https=) |
| EP (1) | EP4347604B1 (https=) |
| JP (1) | JP7833486B2 (https=) |
| CN (1) | CN117651703A (https=) |
| AU (1) | AU2022280804A1 (https=) |
| CA (1) | CA3219490A1 (https=) |
| ES (1) | ES3057101T3 (https=) |
| WO (1) | WO2022251304A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250155550A (ko) | 2023-03-16 | 2025-10-30 | 다케다 야쿠힌 고교 가부시키가이샤 | 매크로시클릭 헤테로시클 화합물 및 이의 용도 |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
| WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
| US20160250224A1 (en) | 2013-09-24 | 2016-09-01 | The Board Of Regents Of The University Of Texas System | Orexin-control of bone formation and loss |
| CA2930693A1 (en) | 2013-11-15 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Methods of treating heart failure with agonists of hypocretin receptor 2 |
| PE20161064A1 (es) | 2013-12-12 | 2016-10-28 | Univ Tsukuba | Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo |
| WO2015147240A1 (ja) | 2014-03-28 | 2015-10-01 | 国立大学法人筑波大学 | 敗血症の予防治療剤 |
| PL3411358T3 (pl) | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
| US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| US20200207734A1 (en) * | 2017-08-03 | 2020-07-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| WO2020167701A1 (en) * | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
| FI4065585T3 (fi) | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| WO2022051583A1 (en) * | 2020-09-03 | 2022-03-10 | Orexia Therapeutics Limited | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists |
| US12006330B2 (en) * | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| US11760747B2 (en) * | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
-
2022
- 2022-05-25 WO PCT/US2022/030841 patent/WO2022251304A1/en not_active Ceased
- 2022-05-25 CN CN202280047652.3A patent/CN117651703A/zh active Pending
- 2022-05-25 ES ES22732772T patent/ES3057101T3/es active Active
- 2022-05-25 CA CA3219490A patent/CA3219490A1/en active Pending
- 2022-05-25 AU AU2022280804A patent/AU2022280804A1/en active Pending
- 2022-05-25 EP EP22732772.3A patent/EP4347604B1/en active Active
- 2022-05-25 JP JP2023572623A patent/JP7833486B2/ja active Active
-
2023
- 2023-11-14 US US18/389,467 patent/US20240174689A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4347604B1 (en) | 2025-12-03 |
| JP7833486B2 (ja) | 2026-03-19 |
| JP2024520396A (ja) | 2024-05-24 |
| WO2022251304A1 (en) | 2022-12-01 |
| CN117651703A (zh) | 2024-03-05 |
| EP4347604C0 (en) | 2025-12-03 |
| ES3057101T3 (en) | 2026-02-26 |
| CA3219490A1 (en) | 2022-12-01 |
| US20240174689A1 (en) | 2024-05-30 |
| WO2022251304A8 (en) | 2023-01-05 |
| EP4347604A1 (en) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4329877B1 (en) | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity | |
| JP7846113B2 (ja) | 置換ピペリジノ化合物及び関連する治療方法 | |
| EP4347604B1 (en) | Substituted carbamate macrocyclic compounds and related methods of treatment | |
| AU2022281345A1 (en) | Substituted fused bicyclic macrocyclic compounds and related methods of treatment | |
| EP4543432A1 (en) | Substituted pyrrolidinyl and piperidinyl compounds and related methods of treatment | |
| WO2023249872A1 (en) | Substituted fused bicyclic compounds and related methods of treatment | |
| AU2023287589A1 (en) | Substituted pyrrolidinyl and piperidinyl compounds and related methods of treatment | |
| WO2023249873A2 (en) | Substituted fused bicyclic compounds and related methods of treatment | |
| HK40099265A (en) | Substituted piperidino compounds and related methods of treatment | |
| HK40099265B (en) | Substituted piperidino compounds and related methods of treatment |